Nuvectis Pharma (NASDAQ:NVCT) Stock, Quote.Headers.trade-ideas

Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Penny Stocks

Small Cap

Trading Ideas

APRN

ATIP

AURC

BFRG

GETY

LUNR

NVCT

RETO

UPTD

YELL

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move.

High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.

10 Short Squeeze Stocks To Watch: Blue Apron, Intuitive Machines, Yellow Corp, Getty Images And More

Long Ideas

News

Insider Trades

Intraday Update

Markets

IBCP

RILY

TCBI

Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.

Insiders Buying Texas Capital Bancshares And 3 Other Stocks

Pre-Market Outlook

MLKN

STCN

Although US stocks closed mixed on Thursday, there were a few notable insider trades.

Insiders Buying Steel Connect And 2 Other Stocks

Nuvectis Pharma Inc

Anthony Scaramucci, who worked very briefly as White House Communications Director under former President Donald Trump, in an interview published on Wednesday shared his insights into the <a href="https://www.benzinga.com/news/24/09/40913930/kamala-harris-moves-from-13-point-deficit-to-7-point-lead-over-trump-in-survey-of-fund-managers-stra">2024 presidential race</a>.
Impressed With Harris: Vice President Kamala Harris has done a good job so far despite her late-entry into the race, said Scaramucci in an <a href="https://www.wsj.com/video/events/anthony-scaramucci-on-harris-vs-trump/C105B408-F8D1-4E0C-8B21-79D02BF0E52D.html?mod=WSJvidctr_upnext_pos0">interview</a> with The Wall Street Journal. When President Joe Biden decided to quit the race and endorsed her, she had to simultaneously do three things &#8211; merging her staff with his re-election team, get the delegates to commit to her and also find a way to be respectful to the president, he said.
The vice president had to get the nomination, knocking the other potentially contenders, and prepare for the debate as well, he said. &#8220;I think she's done an incredible job in a very short period of time,&#8221; he added. 
The critics may still point out that she needs to do more interviews, flesh out her economic agenda and speak with greater clarity about what she wans to do, what her vision is, Scaramucci said. All that is coming and she started the process but she may not do as many interviews as the media would like, he said.
&#8220;If you think about where she was on July 21st and where she is here in the middle of September I think II would give her an A plus in terms of her execution,&#8221; he added.
See Also: <a href="https://www.benzinga.com/news/24/09/40936316/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pro-tr">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a>
How Harris Differs: Scaramucci said the vice president differed from Trump in building a team or coalition. &#8220;If you like President Trump&#8230;. you sort of know what you're getting. You're getting a team of one. It's him. He's in the spotlight,&#8221; the ex-White House aide said.
Trump doesn&#8217;t like other people speaking for him, which was evident when he rebuked his running mate Sen. JD Vance (R-Ohio) during the debate for speaking for him, Scaramucci said. Harris has gone now to a very broad group of people and asked for help from Republicans and Democrats on debate prep, he added. 
To make his case, Scaramucci noted that he, who was a lifelong Republican, was called to go into the spin room and advocate on her behalf, and she got the endorsement of former Republican Congresswoman Liz Cheney and her father and former Vice President Dick Cheney.
&#8220;Think of the coalition that she's building and and think about her willingness to do that,&#8221; he said.
3 Focal Points: Scaramucci said irrespective of who wins, three things are important. The next president should strengthen U.S.&#8217; alliances and move toward the allies and not away from them. &#8220;That would send a very big message to the world that America is committed to peace and long term prosperity for our trading partners and for the cause of freedom around the world,&#8221; he said. Trump, meanwhile, wants to go toward isolationism, he added.
Secondly, the U.S. has to address the<a href="https://www.benzinga.com/general/macro-notification/24/04/38337484/is-the-us-national-debt-unsustainable-we-cant-have-a-deficit-of-7-of-the-gdp"> looming debt crisis, </a>Scaramucci said. &#8220;When you are spending over a trillion dollars of tax receipts on interest payments and you're looking at $2 trillion deficits a year we have to do something about that and we can fix that&#8230; but it would take 15 or 20 years,&#8221; he said. He called upon Americans to back the political leader who is offering a 10-20 year plan to right-size the deficits. 
The third important thing would be to redo the tax code to create more economic incentives for growth in the blue states, Scaramucci said. The state and local income tax deduction limitation that the Trump administration put in, in Dec. 2017 has hurt the overall economy, he said.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>

Politics

Media

Scaramucci: Donald Trump Is A 'Team Of One', Kamala Harris Has 'Done An Incredible Job'

Arab-American voters, represented by 31-year-old Palestinian American Ruwa Romman, face a complex <a href="https://www.benzinga.com/topic/2024-election" target="_blank" rel="noreferrer noopener">dilemma this election season</a> in Georgia.
Romman, a legislator in the swing state, was nominated to represent the Uncommitted National Movement, <a href="https://www.aljazeera.com/features/longform/2024/9/18/denied-the-democratic-convention-stage-ruwa-romman-focuses-on-whats-next" target="_blank" rel="noreferrer noopener">reported</a> Al Jazeera. This protest initiative aims to urge Democratic presidential nominee Kamala Harris to reconsider her support for Israel&#8217;s actions in Gaza.
While she planned to share her family&#8217;s story at the Democratic National Convention in mid-August, she didn&#8217;t get the chance.
Nonetheless, her advocacy outside the convention has propelled her into the national spotlight.
Romman embodies the struggle many Arab-Americans experience as they balance their support for the Democratic Party with criticism of its largely pro-Israel platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40969619/trump-ally-sarah-huckabee-sanders-jabs-kamala-harris-for-not-having-biological-children-doesnt-have" rel="noreferrer noopener">Trump Ally Sarah Huckabee Sanders Jabs Kamala Harris For Not Having Biological Children: &#8220;Doesn&#8217;t Have Anything Keeping Her Humble!&#8221;</a>
Romman was among three speakers proposed by the movement to convey the Palestinian experience at the convention.
In an interview with Al Jazeera, she mentioned that, had she been allowed to speak, her address would have included an endorsement for Harris.
Romman viewed her potential speech as a chance to humanize the plight of Palestinians, who have lost over 41,250 lives in the ongoing conflict. When questioned about whether she would rule out endorsing Harris, Romman indicated that she didn&#8217;t have a definite answer. She mentioned that she had extended her endorsement, but noted that neither the Harris campaign nor the DNC acknowledged it.
Regarding the issue of an official endorsement, she remarked that it was more a matter for them to decide, rather than for her.
Born in Jordan, Romman made history in 2022 as the first Muslim woman elected to the Georgia State House of Representatives. She was part of a record wave of 153 Muslim-American candidates who won office during that year&#8217;s midterm elections.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40969515/amazon-going-nuclear-hiring-plans-indicate-company-may-be-eyeing-nuclear-to-meet-energy-needs" target="_blank" rel="noreferrer noopener">Amazon Going Nuclear? Hiring Plans Indicate Company May Be Eyeing Nuclear To Meet Energy Needs</a></li>
</ul>

General

Georgia's Ruwa Romman: First Muslim Woman in State House Navigates Complex Political Landscape

<a href="https://www.benzinga.com/topic/kevin-oleary">Kevin O'Leary</a>, the outspoken investor known as <a href="https://www.benzinga.com/startups/24/09/40839130/were-looking-for-a-real-a-e-and-youre-in-kevin-oleary-on-how-he-got-his-infamous-shark-tank-role">&#8220;Mr. Wonderful&#8221; from Shark Tank</a>, didn't always plan on being a business mogul. His first love was something completely different: photography.&nbsp;
Fresh out of high school, Kevin dreamed of turning his passion into a career. He even set up a lab in his basement and was doing everything he loved. But his father had a harsh dose of reality for him.
Don't Miss:
<ul>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
<li>Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a></li>
</ul>
"You're not good enough and you'll starve to death," his dad bluntly told him. His father pushed him to go to college and earn a degree, telling him not to follow his heart. This tough love turned out to be some of the best advice Kevin could have received, even though it might have felt like his aspirations were being dashed.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When I first wanted to be a photographer, My dad told me I wasn&#39;t good enough—I&#39;d starve. So, I got an MBA and ended up building and selling a company for $4.2 billion. It all came together—business, creativity, and the drive to win. I wouldn&#39;t change a thing. <a href="https://t.co/Xv8ttJFk2V">pic.twitter.com/Xv8ttJFk2V</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1836031341428633623?ref_src=twsrc%5Etfw">September 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50/share with a $1,000 minimum.</a>
Kevin took his father's advice and went to college, eventually earning an MBA. Though it wasn't part of his original plan, this degree would later be a game-changer. He soon found a way to merge his passion for photography and production with his business skills, launching his first company, Special Event Television, which produced programming for East Coast hockey games.
That first venture set the stage for a highly successful career. Kevin and his co-founders eventually sold the company and Kevin used the money to start his next venture, a software business called Softkey, which he later sold for $4.2 billion.
Trending: Unlock a $400 billion opportunity by investing in the future of EV infrastructure on<a href="https://www.benzinga.com/money/dunamis-1"> this startup already valued at $50 million with just $500</a>.
Still in his mid-30s,<a href="https://www.benzinga.com/startups/24/09/40776473/it-was-boring-kevin-oleary-explored-every-beach-on-earth-after-he-first-got-rich-but-the-highs-and-l"> Kevin decided to retire</a> and live the kind of financially independent life that most of us can only imagine. He traveled the world, visiting the most beautiful beaches and other stunning locations. However, something unexpected happened – he found himself bored in spite of the luxury and endless travel. &#8220;I went to every beach on Earth,&#8221; he says, but after three years, &#8220;It was really boring.&#8221;
Trending: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible.</a>
The excitement of creating something, taking chances and participating in the business world was something he missed. Retirement proved unsatisfactory, even though it seemed like the ultimate goal.
Apart from his father giving him tough advice, Kevin also credits his mother for giving him some of the best financial advice he ever received. <a href="https://www.benzinga.com/general/24/05/39037170/shark-tanks-kevin-oleary-declares-the-best-advice-he-ever-received-from-his-mom-spend-the-interest-n">She taught him</a> and his brother a simple but effective lesson: "Boys, never spend the principal, only the interest." Although he didn&#8217;t fully understand it then, this lesson has guided him throughout his life and career.
Kevin O'Leary's life story shows that success typically doesn't follow a straight line but often involves following difficult-to-hear advice.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Startups

Kevin O'Leary's Dad Warned Him He'd 'Starve To Death' If He Pursued His Passion. Getting An MBA Ended Up Changing His Life

<a href="https://www.benzinga.com/topic/donald-trump" target="_blank" rel="noreferrer noopener">Donald Trump</a> returned to North Carolina on Saturday to campaign in Wilmington, a key battleground in the upcoming November election.
However, he was without Lt. Gov. Mark Robinson, the GOP gubernatorial nominee and one of Trump&#8217;s primary supporters in the state, <a href="https://apnews.com/article/trump-mark-robinson-north-carolina-wilmington-1bc79594567860c9ffe7f44375fac847" target="_blank" rel="noreferrer noopener">reported</a> AP News.
A CNN <a href="https://edition.cnn.com/2024/09/19/politics/kfile-mark-robinson-black-nazi-pro-slavery-porn-forum/index.html" target="_blank" rel="noreferrer noopener">report</a> on Thursday regarding Robinson&#8217;s inflammatory remarks about race, gender, and sexual orientation <a href="https://www.benzinga.com/news/24/09/40968051/republicans-in-damage-control-mode-after-mark-robinsons-remarks-spark-concern-for-trump-campaign-goi" target="_blank" rel="noreferrer noopener">has left the Republicans scrambling</a>.
As per the CNN report, Robinson commented on a pornography website&#8217;s message board, where he self-identified as a &#8220;Black Nazi&#8221; and expressed a desire for the return of slavery.
Democrats, on the other hand, are highlighting Robinson&#8217;s connections to other candidates, including Trump, who has previously praised the North Carolina lieutenant governor.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/24/09/40968051/republicans-in-damage-control-mode-after-mark-robinsons-remarks-spark-concern-for-trump-campaign-goi" rel="noreferrer noopener"> Republicans In Damage Control Mode After Mark Robinson&#8217;s Remarks Spark Concern For Trump Campaign: &#8216;Going To Have An Up-Ballot Effect,&#8217; Says GOP Consultant</a>
Robinson was not scheduled to attend the Wilmington event, said AP News, citing two individuals with knowledge of the situation, who requested anonymity.
Although Robinson secured victory in his GOP gubernatorial primary back in March, he has fallen behind Democratic nominee Josh Stein, the state attorney general, in several recent polls.
State Republican leaders continue to support Robinson, but his choice to persist with his campaign might jeopardize the GOP&#8217;s chances in other crucial races, including Trump&#8217;s efforts in a battleground state he has won twice before.
Trump has consistently expressed admiration for Robinson, a Black politician, calling him a figure reminiscent of Martin Luther King, but with added intensity. When endorsing Robinson prior to the GOP gubernatorial primary, Trump stated that he believes Robinson surpasses King in significance, AP News added.
While presidential candidates have focused more on the Rust Belt states like Pennsylvania, Michigan, and Wisconsin, both Trump and Harris have made several visits to North Carolina, underscoring the state&#8217;s significance.
After Biden exited the race in July, Trump organized his first major rally there, shifting his attention entirely toward Harris.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Controversial Ally Mark Robinson Absent From Donald Trump Rally In Pivotal North Carolina

Mary Trump, a psychologist and author, last week shared her thought on her uncle <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a><a href="https://www.benzinga.com/topic/donald-trump">&#8216;s</a> psychology and also the media sane-washing him.
Lover Of Violence: Mary Trump called her uncle a lover of violence, especially when it is committed on his behalf, <a href="https://www.marytrump.org/p/the-bringer-of-violence">said</a> Mary Trump in a Substack post. Weighing in on a second assassination attempt against the former president, she noted that it was only a few days before the incident that he refused to condemn the bomb threats, school evacuations, and general sense of terror in Springfield, Ohio, that he and his running mate Sen. JD Vance (R-Ohio) have unleashed by their &#8220;vicious targeting of Haitian immigrants who live and work there.&#8221;
&#8220;Threats of violence and actual violence from the right are now a regular part of our political discourse and behavior —Donald makes sure of that on an almost daily basis,&#8221; she said.
Mary Trump noted that in early days of her uncle&#8217;s 2016 campaign, he encouraged rally goers to assault protesters. &#8220;Before and during the assault on the Capitol on Jan. 6, 2021, Donald encouraged and stoked violence and people listened,&#8221; she said. 
&#8220;Every day, Americans pay the price while Donald sets the world on fire with his provocations and then spends the day playing golf, completely insulated from the chaos he sows,&#8221; she added.
The former president believes that the only way to maintain his grip on power is to &#8220;keep us divided, angry, and afraid,&#8221; Mary Trump said.
&#8220;America can't go on like this,&#8221; she said, adding that &#8220;I worry about what will happen in the next 50 days and the uncertain weeks that will follow.&#8221; 
See Also: <a href="https://www.benzinga.com/content/40955366/anthony-scaramucci-says-trumps-3-legged-stool-strategy-of-racism-misogyny-and-anti-immigration-will">Anthony Scaramucci Says Trump&#8217;s 3-Legged Stool Strategy Of &#8216;Racism, Misogyny And Anti-Immigration&#8217; Will Misfire: Here&#8217;s What Would Seal The Deal For Kamala Harris</a>
Sane-washing Trump: Mary Trump also <a href="https://www.youtube.com/watch?v=fzAaOdvkIDw">shared</a> a MSNBC interview in which she discussed about the media sane-washing Donald Trump. &#8220;They are just pretending that he said these understandable, coherent things but much worse than that they are imbuing his meaningless statements with meaning that is not there,&#8221; she said. This makes the former president more serious and less delusional than he actually is, she added.
For years now, it has been told that some of the most disqualifying things about Donald Trump are baked in and so nobody cares about them anymore, the psychologist said. But she called it as a &#8220;wrong take.&#8221; This &#8220;gives him an enormous advantage because he can do anything and we are all just supposed to assume that that&#8217;s just fine and it gives him permission to get away with worse,&#8221; she said. 
Although this isn&#8217;t anything new, it is now just increasingly less hinged, more delusional, more dangerous, Mary Trump said, adding that the people he surrounds himself with have always been awful, they too are becoming more dangerous to democracy and to American citizens.
Mary Trump also delved into her uncle&#8217;s claims about <a href="https://www.benzinga.com/news/24/09/40937559/jd-vances-unverified-rumors-about-haitian-immigrants-stir-gop-discomfort-distracting-from-real-issue">Haitian illegal immigrants eating pets in Springfield, Ohio</a>. This is just the latest example of something he has been doing for years. This is stochastic terrorism,&#8221; she said, adding that this is deadly serious.
&#8220;Donald Trump has and will get people killed because of his dangerous rhetoric and the fact that he is willing to stop at nothing if he thinks demeaning the most vulnerable people among us is going to get him another vote,&#8221; Mary Trump said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>

Mary Trump Says Americans Pay The Price As Her Uncle Sets World On Fire With His Provocations: 'I Worry About What Will Happen'

Wall Street is rejoicing as the Federal Reserve&#8217;s half-point rate cut triggers a market rally, even amidst rising apprehensions <a href="https://www.benzinga.com/general/market-summary/24/08/40429168/s-p-500-records-best-week-of-the-year-amid-favorable-economic-reports-what-really-drove-th">about inflated valuations</a>.
What Happened: The Federal Reserve&#8217;s lenient approach has uplifted the economic forecast, resulting in a jump in U.S. stocks and commodities, and a reduction in bond market volatility. 
The Nasdaq 100 experienced its most significant two-week surge since November, dismissing worries that the Fed chief had postponed concluding a two-year fight against inflation.
Nonetheless, inflated valuations are emerging as a substantial hurdle, leaving little margin for mistakes if any event disrupts investors&#8217; large-scale bets, <a href="https://www.bloomberg.com/news/articles/2024-09-20/risk-appetites-rage-as-powell-proves-hero-in-high-priced-markets?srnd=homepage-americas&amp;sref=TBDibEcD">reports</a> Bloomberg.
A model adjusting S&amp;P 500 earnings yields and 10-year Treasury rates for inflation suggests that cross-asset pricing is now higher than at the commencement of all previous 14 Fed easing cycles, typically linked with recessions.
Also Read: <a href="https://www.benzinga.com/news/24/08/40541128/fed-chair-powells-signal-sets-stage-for-rate-global-central-banks-hint-at-interest-rate-cuts-in-revi">Fed Chair Powell&#8217;s Signal Sets Stage For Global Rate Cuts As Central Banks Aim To Revive Economy</a>
Lauren Goodwin, economist and chief market strategist at New York Life Investments, cautions that while high prices are just one factor contributing to a multifaceted market environment, they amplify market vulnerability if any other aspect goes awry.
U.S. stocks surged, propelling the S&amp;P 500&#8217;s total return for 2024 above 20%. The index leaped 1.7% on Thursday, marking its 39th record close of the year, following the Fed&#8217;s rate cut and data indicating labor market resilience.
However, many stock-valuation measures are stretched, including the Buffett indicator, which divides the total market capitalization of U.S. stocks by the total dollar value of the nation&#8217;s GDP. This indicator is near a record high, at a time when Warren Buffett has recently downsized some high-profile equity holdings.
Why It Matters: Despite these concerns, the rally in U.S. stocks persists, justified by earnings growth keeping pace with high valuations.
However, the potential for disappointment is high in the Treasury market, where futures trading continues to anticipate more interest-rate cuts than Fed policymakers themselves see as likely over the next year.
Read Next
<a href="https://www.benzinga.com/news/24/08/40431394/brighter-outlook-goldman-sachs-optimistic-on-u-s-economy-cuts-recession-risk-down-to-20" target="_blank" rel="noreferrer noopener">Brighter Outlook: Goldman Sachs Optimistic On U.S. Economy, Cuts Recession Risk Down To 20%</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Fed Rate Cut Fuels Market Rally Amidst Valuation Fears

In a recent podcast interview, Facebook founder Mark Zuckerberg shared his parenting philosophy, emphasizing the importance of individuality over fame.
What Happened: Zuckerberg recounted a conversation with his 7-year-old daughter August Chan Zuckerberg, where he encouraged her to aspire to be herself rather than a celebrity. This discussion was prompted by her desire to be like Taylor Swift.
According to a report <a href="https://www.businessinsider.com/mark-zuckerberg-taylor-swift-daughter-parenting-lesson-2024-9">by</a> Business Insider, Annie Wright, a therapist who works with affluent parents, praised Zuckerberg&#8217;s advice. She noted that parents often grapple with their children&#8217;s growing desire to become influencers. Wright urges parents to help their children cultivate a strong sense of self-worth and individuality, instead of pursuing popularity.
According to the outlet, Zuckerberg said in the interview, &#8220;I was like, &#8216;But you can&#8217;t. That&#8217;s not available to you. And she thought about it and she&#8217;s like, &#8216;Alright when I grow up I want people to want to be like August Chan Zuckerberg, and I was like, &#8216;Hell yeah. Hell yeah.'&#8221;
Wright also highlighted that children from high-achieving families often experience intense pressure to succeed, leading to feelings of inadequacy. She promotes the idea of parents downplaying goals like fame and having open dialogues about its drawbacks.
Also Read: <a href="https://www.benzinga.com/news/22/12/30195280/elon-musks-ex-girlfriend-grimes-says-mark-zuckerberg-wildly-under-qualified-to-run-metaverse">Elon Musk&#8217;s Ex-Girlfriend Grimes Says Mark Zuckerberg &#8216;Wildly Under Qualified&#8217; To Run Metaverse</a>
&#8220;His advice to his daughter to aspire to be herself, not Taylor Swift or some other icon, I do think it&#8217;s an important reminder for all parents,&#8221; Wright told the outlet.
Part of Zuckerberg&#8217;s parenting strategy includes assigning chores to his children, a practice Wright believes is an effective way to teach vital life skills, particularly in affluent families. 
She stated, &#8220;Chores create an understanding that rewards come from effort, not entitlement.&#8221;
Also Read: <a href="https://www.benzinga.com/general/entertainment/24/09/40869299/mother-sells-taylor-swift-tickets-over-stars-endorsement-of-kamala-harris-im-gonna-shake-it">Mother Sells Taylor Swift Tickets Over Star&#8217;s Endorsement Of Kamala Harris: &#8216;I&#8217;m Gonna Shake It Off, And I&#8217;m Done With You&#8217;</a>
Why It Matters: Zuckerberg&#8217;s parenting approach offers a unique perspective in a society where fame and celebrity status are often glamorized. His advice underscores the importance of self-worth and individuality, values that can help children navigate the pressures of growing up in high-achieving families. 
Furthermore, his emphasis on chores as a means to teach life skills provides a practical approach to parenting that encourages effort and discourages entitlement. 
This advice is particularly relevant in today&#8217;s digital age, where the allure of becoming an influencer can often overshadow the importance of personal growth and self-discovery.
Read Next
<a href="https://www.benzinga.com/news/24/09/40867264/big-techs-security-spending-spree-zuckerberg-leads-in-lavish-security-measures">Big Tech&#8217;s Security Spending Spree: Zuckerberg Leads In Lavish Security Measures</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Social Media

Zuckerberg Tells His Daughter She Can't Be Like Taylor Swift: 'You Can't Do It, That's Not Available To You'

A recent survey revealed that more than half of voters back pop star <a href="https://www.benzinga.com/topic/taylor-swift" target="_blank" rel="noreferrer noopener">Taylor Swift</a><a href="https://www.benzinga.com/topic/taylor-swift" target="_blank" rel="noreferrer noopener">&#8216;s</a> initiative to encourage her fans to <a href="https://www.benzinga.com/general/entertainment/24/09/40869299/mother-sells-taylor-swift-tickets-over-stars-endorsement-of-kamala-harris-im-gonna-shake-it" target="_blank" rel="noreferrer noopener">participate in this year&#8217;s election</a>.
However, this support has dropped by 15 points since February, partly due to a conspiracy theory suggesting the Super Bowl was rigged, <a href="https://thehill.com/blogs/in-the-know/4888659-taylor-swift-voter-turnout-effort/?tbref=hp\" target="_blank" rel="noreferrer noopener">reported</a> The Hill, citing the latest Monmouth University <a href="https://www.monmouth.edu/polling-institute/reports/monmouthpoll_us_091924/" target="_blank" rel="noreferrer noopener">poll</a>.
&#8220;Interestingly, support for the singer&#8217;s get-out-the-vote (GOTV) efforts were much higher <a href="https://www.monmouth.edu/polling-institute/reports/monmouthpoll_us_021424/" target="_blank" rel="noreferrer noopener">seven months ago</a>, when she was the subject of a debunked conspiracy theory around the election and the Super Bowl,&#8221; said Patrick Murray, director of the independent Monmouth University Polling Institute.
Swift has been recognized for directing a massive influx of over 330,000 visitors to vote.gov,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/entertainment/24/09/40807445/taylor-swift-says-i-will-be-casting-my-vote-for-kamala-harris-and-tim-walz-takes-a-dig-at-j" rel="noreferrer noopener">following her public endorsement</a>&nbsp;of Vice President&nbsp;Kamala Harris. This surge occurred less than 24 hours after Swift&#8217;s endorsement after the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/09/40806876/final-showdown-trump-and-harris-face-off-in-intense-debate-just-eight-weeks-before-election-day" rel="noreferrer noopener">debate between</a>&nbsp;Harris and former President&nbsp;Donald Trump.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40870369/trumps-i-hate-taylor-swift-met-with-witty-response-from-harris-campaign-the-american-people-want-to" rel="noreferrer noopener">Trump&#8217;s &#8216;I Hate Taylor Swift&#8217; Met With Witty Response From Harris Campaign: &#8216;The American People Want To Be Out Of The Woods&#8217;</a>
However, the poll shows that 53% of voters support Taylor Swift&#8217;s efforts to encourage her fans to vote, while 35 percent disapprove, The Hill added. Additionally, 12% of respondents indicated that they were unsure.
&#8220;Republicans were wary of Swift all along. What we don&#8217;t know is whether this will have any effect on the part of her fan base who already leans right,&#8221; Murray added.
Swift is currently in a relationship with Kansas City Chiefs tight end Travis Kelce and was present at the team&#8217;s Super Bowl game against the San Francisco 49ers in Las Vegas. During that time, a conspiracy theory emerged suggesting that the game might be manipulated to benefit the Chiefs and maximize exposure for a potential Swift endorsement of President Biden.
No evidence supported this theory, nor had Swift made any endorsements at that point. However, Monmouth noted a significant decline in support for Swift&#8217;s voting initiatives following the conspiracy, the report added.
Despite Taylor Swift&#8217;s endorsement of the Democrats, an ABC News/Ipsos poll conducted earlier this week revealed that 81% of respondents believe her support for Kamala Harris will not affect their voting decisions.
Only 6% indicated they were more likely to vote for Harris due to Swift&#8217;s endorsement, while 13% said it made them less inclined to support the Democratic ticket, The Hill added.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40866592/swifties-rally-for-kamala-harris-taylor-swift-superfan-organizes-online-push-for-democratic-ticket" target="_blank" rel="noreferrer noopener">Swifties Rally For Kamala Harris: Taylor Swift Superfan Organizes Online Push For Democratic Ticket</a></li>
</ul>

Support For Taylor Swift's Get-Out-The-Vote Efforts Have Dropped 15 Points Since February Amid Super Bowl Conspiracy Theory

Employees at OpenAI have voiced their dissatisfaction with the company&#8217;s proposed new logo, which they have described as &#8220;ominous&#8221; <a href="https://www.benzinga.com/news/24/03/37440684/openais-sam-altman-has-an-estimated-2-billion-net-worth-and-much-of-it-doesnt-come-from-ai">and lacking in creativity</a>.
What Happened: The proposed logo – a large black &#8220;O&#8221; – was revealed at a recent company-wide meeting. This new design is a stark contrast to the current hexagonal flower symbol, which was designed to symbolize &#8220;precision, potential, and optimism.&#8221;
The unveiling of the new design was met with shock and disapproval, with some employees openly expressing their dislike during the meeting, <a href="https://fortune.com/2024/09/20/openai-staffers-unhappy-new-logo-design-ominous/">reports</a> Fortune. 
Insiders suggest that the logo redesign is part of a larger company overhaul scheduled for 2025. This revamp aligns with a planned significant modification to OpenAI&#8217;s corporate structure and an increased emphasis on revenue and investors.
The redesign process, which began about a year ago, is being handled by an internal team. This team consists of new hires from creative agencies and fields such as graphic design. The company&#8217;s current logo, referred to as &#8220;our most recognizable brand element,&#8221; was also developed internally.
Also Read: <a href="https://www.benzinga.com/news/24/09/40764804/whats-the-secret-openai-is-battling-to-keep-co-founders-files-confidential-heres-why">What&#8217;s The Secret? OpenAI Is Battling To Keep Co-Founder&#8217;s Files Confidential, Here&#8217;s Why</a>
Despite the strong reactions, the design of the new logo may undergo further changes, considering the staff&#8217;s attachment to the current logo and the negative feedback received. The final design is expected to be revealed as early as next year.
Why It Matters: The logo redesign is indicative of the broader changes taking place within OpenAI. As the company shifts its focus towards revenue and investors, it is also altering its corporate structure and brand identity. 
The strong reactions from employees highlight the significance of these changes and the potential impact they could have on the company&#8217;s culture and public perception. 
The final design of the logo, expected to be unveiled next year, will be a key indicator of the direction OpenAI is taking in this new phase of its evolution.
Read Next
<a href="https://www.benzinga.com/news/24/07/39763462/whistleblowers-accuse-openai-of-hindering-staff-from-reporting-ai-risks" target="_blank" rel="noreferrer noopener">Whistleblowers Accuse OpenAI Of Hindering Staff From Reporting AI Risks</a>
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

OpenAI's Employees See This Latest Creation As 'Ominous' – What Is It?

Mark Zuckerberg, CEO of Meta, has been seen sporting luxury watches that rival the <a href="https://www.benzinga.com/news/24/07/39999229/dont-look-now-but-zuckerbergs-threads-is-picking-up-steam">cost of a Tesla Cybertruck</a>.
What Happened: Zuckerberg was recently seen wearing a De Bethune DB 25 Starry Varius watch during an <a href="https://www.youtube.com/watch?v=QciJ9ubeLQk">interview</a>.
According to the report <a href="https://nypost.com/2024/09/19/lifestyle/mark-zuckerberg-wears-watch-that-costs-as-much-as-a-cybertruck/">by</a> The New York Post, this luxury timepiece is estimated to be worth between $90,000 and $95,700, nearly the price of a Tesla Cybertruck, which is listed at $99,990.
Earlier this month, Zuckerberg was photographed on Instagram alongside his wife, Priscilla Chan, wearing a Patek Phillipe watch — a 5236P model, which carries a price tag of more than $141,000.
Also Read: <a href="https://www.benzinga.com/news/24/09/40867264/big-techs-security-spending-spree-zuckerberg-leads-in-lavish-security-measures">Big Tech&#8217;s Security Spending Spree: Zuckerberg Leads In Lavish Security Measures</a>
This change in Zuckerberg&#8217;s style is a noticeable departure from his typical wardrobe of hoodies, jeans, and sneakers. His new fashion choices include designer pieces like an Alexander McQueen suit decorated with silver dragonflies.
Despite the speculation surrounding his style evolution, a spokesperson for Meta confirmed to The Times that Zuckerberg &#8220;mostly buys clothes he finds on Instagram&#8221; and occasionally seeks advice for formal events and occasions.
Why It Matters: Venky Ganesan, a partner at Menlo Ventures, suggests that Zuckerberg&#8217;s style evolution could be &#8220;very good for business.&#8221; 
As the CEO of a major tech company, his personal brand and image can influence public perception of the company. His shift towards more luxurious attire could reflect the company&#8217;s growth and success.
Read Next
&nbsp;<a href="https://www.benzinga.com/news/23/03/31129297/zuckerbergs-life-changing-advice-to-young-people" target="_blank" rel="noreferrer noopener">Zuckerberg&#8217;s Life-Changing Advice To Young People</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Mark Zuckerberg Flaunts Watches Valued at a Cybertruck's Price

Many Americans are banking on working longer to make up for a <a href="https://www.benzinga.com/personal-finance/24/08/40295808/youre-40-50-or-60-do-you-know-how-much-you-should-have-saved-for-retirement-by-now">lack of retirement savings</a>. According to a recent CNBC and SurveyMonkey survey, about 27% of workers plan to stay employed during their retirement years to boost their income.&nbsp;
The poll, conducted in early August, included over 6,600 U.S. adults, split between retirees and those still in the workforce.
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a></li>
</ul>
It's a strategy that sounds solid at first glance. After all, staying employed into your 60s or 70s should allow you to continue earning money while giving your retirement savings more time to grow. But according to financial experts, this plan might not be as foolproof as it seems.
The Risk of Working Longer
While extending your working years is appealing, it doesn't always go according to plan. Health issues or unexpected layoffs can suddenly throw a wrench in those plans. "It sounds great on paper," said Philip Chao, founder of Experiential Wealth in Maryland. "But reality could be very different."
If workers are forced out of the job market sooner than expected, they may find themselves scrambling to stretch out their retirement savings, and that's where things can get tricky.
Trending: <a href="https://www.benzinga.com/money/charlie-munger-100k">Charlie Munger said if you want to be rich, &#8220;find a way to get your hands on $100,000&#8221; — here&#8217;s what he means.</a>
Early Retirement Happens More Often Than You Think
Data shows that many Americans end up retiring earlier than they intended. According to a Gallup poll, a consistent five-year gap exists between when people expect to retire and when they do. In 2023, for instance, non-retirees anticipated working until age 66, but most retirees had <a href="https://www.benzinga.com/personal-finance/24/04/38439971/should-you-begin-collecting-social-security-at-62-67-or-70-the-right-answer-may-depend-on-your-b">left the workforce by 62</a>.
This trend isn't new. Research from the <a href="https://www.ebri.org/docs/default-source/rcs/2023-rcs/rcs_23-fs-2.pdf?sfvrsn=708d392f_4#:~:text=The%20RCS%20has%20consistently%20found,'%20expectations%20and%20retirees'%20experiences.">Employee Benefit Research Institute</a> (EBRI) shows that 46% of retirees <a href="https://www.benzinga.com/personal-finance/24/06/39497325/the-average-millennial-expects-to-retire-before-60-why-many-think-this-is-unattainable">left the workforce earlier than planned</a>. So while a third of workers say they aim to retire at 70 or later – or maybe never – only 6% of retirees manage to stick around that long.
Trending: The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a>
The "Escape Valve" That Might Not Work
Many Americans rely on the idea of pushing back retirement as a kind of "escape valve" for financial security. However, as Chao puts it, "saying it and doing it are two totally different things." He warns that this assumption could be a "very dangerous" gamble.
The reasons for those who retire earlier than expected are often out of their control. According to the EBRI survey, 35% retired early due to health issues or disabilities, while 31% faced company-related changes like layoffs.
Working longer seems like a simple solution to building up retirement funds, but reality is far more unpredictable. Life throws curveballs, and relying too much on a late retirement may not be the <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">safety net people think it is</a>. Having other options in place is crucial because sometimes, life has other plans.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>

Personal Finance

People Who Don't Save Enough For Retirement Think Working Longer Will Help – But Experts Warn This 'Escape Valve' Is A Dangerous Gamble

The U.S. Securities and Exchange Commission (SEC) is preparing to reprimand Elon Musk for his absence from a scheduled hearing. This testimony is part of an ongoing investigation into Musk&#8217;s $44 billion acquisition of X, <a href="https://www.benzinga.com/news/24/08/40147580/heres-how-an-elon-musk-backed-pac-harnesses-voter-data-to-support-donald-trump">previously known as Twitter</a>.
What Happened: Musk was expected to testify before the SEC on September 10. However, Musk&#8217;s lawyer informed the SEC that Musk had to urgently travel to Cape Canaveral, Florida for the launch of SpaceX&#8217;s Polaris Dawn, thereby missing the testimony.
According to a report <a href="https://thehill.com/policy/technology/4891840-sec-reprimands-elon-musk-twitter/">by</a> The Hill, this is the second time Musk has failed to appear before the SEC in relation to the probe into his acquisition of the social media platform, now known as X.
&#8220;Musk has now failed to appear before the SEC twice: first in September 2023, in defiance of a lawful administrative subpoena, and last week, in defiance of a clear court order,&#8221; stated SEC&#8217;s lawyer Robin Andews in the court filing.
Alex Spiro, Musk&#8217;s lawyer, has labeled the SEC&#8217;s sanctions as &#8220;drastic&#8221; and confirmed that a new date for the testimony has been agreed upon. 
Also Read: <a href="https://www.benzinga.com/news/24/09/40866970/new-book-reveals-elon-musks-twitter-buy-fumble-and-mix-up-over-grimes-baby-name">New Book Reveals Elon Musk&#8217;s Twitter Buy Fumble And Mix-Up Over Grimes&#8217; Baby Name</a>
He emphasized that the rescheduling was due to a &#8220;critical&#8221; rocket launch and dismissed concerns of a similar emergency happening in the future.
Meanwhile responding to SEC&#8217;s claim Musk went on X and said that &#8216;actual crimes go unpunished&#8217;. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While actual crimes go unpunished
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1837387386637930896?ref_src=twsrc%5Etfw">September 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The SEC&#8217;s reprimand of Musk underscores the regulatory body&#8217;s commitment to enforcing compliance, even when dealing with high-profile individuals like Musk. 
This incident also highlights the challenges Musk faces in balancing his responsibilities as CEO of Tesla and his other ventures, such as SpaceX. 
The SEC&#8217;s ongoing probe into Musk&#8217;s acquisition of Twitter, now X, is a significant event, given the size of the deal and the potential implications it could have on the social media landscape. 
The outcome of this investigation could set a precedent for future tech acquisitions and regulatory compliance.
Read Next
<a href="https://www.benzinga.com/news/23/01/30551173/elon-musk-testifies-he-could-have-taken-tesla-private-with-funds-from-spacex-in-2018">Elon Musk Testifies He Could Have Taken Tesla Private With Funds From SpaceX In 2018</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Elon Musk Faces SEC Backlash Over Missed Testimony, Quips 'Actual Crimes Go Unpunished'

The popular party game company Cards Against Humanity has hit Elon Musk&#8217;s SpaceX with a $15 million lawsuit. The lawsuit alleges that SpaceX trespassed and <a href="https://www.benzinga.com/news/24/09/40762349/x-faces-major-advertiser-exodus-amid-string-of-elon-musk-controversies">caused damage to their land in Texas</a>.
What Happened: Cards Against Humanity has accused SpaceX of trespassing and littering on their land near the Texas-Mexico border. 
The land, which was bought through crowdfunding in 2017, was reportedly cleared of vegetation and used as a dumping ground by SpaceX&#8217;s Starbase.
The lawsuit was lodged in a Texas court last week. Cards Against Humanity alleges that SpaceX offered to buy the land for less than half its value, giving them a 12-hour ultimatum to accept the offer. 
Also Read: <a href="https://www.benzinga.com/news/24/09/40866970/new-book-reveals-elon-musks-twitter-buy-fumble-and-mix-up-over-grimes-baby-name">New Book Reveals Elon Musk&#8217;s Twitter Buy Fumble And Mix-Up Over Grimes&#8217; Baby Name</a>
In a <a href="https://www.elonowesyou100dollars.com/">letter</a> posted online, the company said, &#8220;Elon Musk's SpaceX was building some space thing nearby, and he figured he could just dump his s&#8212; all over our gorgeous plot of land without asking. After we caught him, SpaceX gave us a 12-hour ultimatum to accept a lowball offer for less than half our land's value.&#8221;
In a humorous twist, the company suggested they would accept Twitter.com as compensation, a nod to Musk&#8217;s recent $44 billion acquisition of the social media platform.
Despite SpaceX purchasing neighboring lots, it has allegedly ignored the &#8220;no trespassing&#8221; sign on Cards Against Humanity&#8217;s land. 
The lawsuit claims that the land has been used as a staging area for SpaceX&#8217;s construction projects, causing damage and straining the game company&#8217;s relationship with its supporters.
Why It Matters: This lawsuit comes at a time when SpaceX has been expanding its operations in Texas, with the purchase of several neighboring lots. 
The alleged trespassing and damage to Cards Against Humanity&#8217;s land could potentially impact SpaceX&#8217;s reputation and future expansion plans. 
Furthermore, the lawsuit could set a precedent for other landowners in the area who may have similar grievances. As of now, SpaceX has not commented on the lawsuit.
Read Next
<a href="https://www.benzinga.com/news/22/03/26313551/elon-musk-admits-he-is-lonely-after-his-split-with-grimes-says-hes-not-afraid-to-die-2" target="_blank" rel="noreferrer noopener">Elon Musk Says You Need 2 Things To Be ‘Fully Happy,&#8217; If You Lack 1 You&#8217;ll Be ‘Half Happy&#8217;</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Party Game Company Sues Musk's SpaceX: A $15M Land Dispute That Could Change Everything

Famed data analyst Nate Silver&#8216;s election forecast shows Kamala Harris with a better chance of winning the presidency than Donald Trump <a href="https://www.benzinga.com/news/24/09/40669286/harris-vs-trump-this-candidate-leading-in-numerous-polls-transforming-political-landscape">for the first time since August 28</a>.
What Happened: According to his Silver Bulletin <a href="https://www.natesilver.net/p/nate-silver-2024-president-election-polls-model">site</a>, Silver says the race is still up in the air, and the lead could potentially change again due to the forecast being so close to a 50/50 split.
&#8220;Harris is technically the favorite in the model for the first time since Aug. 28 — but the race is a toss-up,&#8221; Silver wrote. He currently gives Harris a 52 percent chance of victory. FiveThirtyEight, founded by but no longer affiliated with Silver, uses a different model that shows Harris with a 60 percent chance of defeating Trump.
Also Read: <a href="https://www.benzinga.com/news/24/09/40869086/trump-vs-harris-new-poll-reveals-post-debate-swing-towards-this-candidate-in-key-state">Trump Vs Harris: New Poll Reveals Post-Debate Swing Towards This Candidate In Key State</a>
Despite Harris&#8217; perceived victory in the presidential debate, Silver&#8217;s model indicates that neither candidate lost or gained much support.
However, Harris did experience a slight increase in support around August 23, following her official nomination as the party&#8217;s candidate at the Democratic National Convention in Chicago, <a href="https://thehill.com/homenews/campaign/4890948-vice-president-harris-leads-trump-poll/">reports</a> Business Insider.
Also Read:&nbsp;<a href="https://www.benzinga.com/news/24/09/40866884/trump-vs-harris-tense-standoff-in-nail-biter-polls" target="_blank" rel="noreferrer noopener">Trump Vs. Harris: Tense Standoff In Nail-Biter Polls</a>
In crucial swing states, Silver&#8217;s model shows Harris leading in Pennsylvania, Wisconsin, Michigan, Nevada, and Minnesota, while Trump is ahead in North Carolina, Georgia, and Arizona.
The Hill/Decision Desk HQ&#8217;s poll aggregation also shows Harris leading Trump nationally by a 3.6 percentage point margin. However, Silver warned that neither side should be overly confident as &#8220;stranger things have happened than a candidate who was behind in the polls winning.&#8221;
Read Also
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades?utm_source=BZprocontent092124" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It Matters: The fluctuating leads in the election forecast underscore the unpredictable nature of the race. 
The fact that Harris has managed to surpass Trump for the first time since August indicates a potential shift in voter sentiment. However, with the race being so close, it&#8217;s clear that the outcome is far from decided.
As the election draws nearer, the focus on key swing states will intensify. The leads that Harris and Trump hold in these states could ultimately determine the election&#8217;s outcome. 
Therefore, the candidates&#8217; strategies in these states will be crucial in the coming weeks.
Read Next
<a href="https://www.benzinga.com/news/24/08/40667209/trump-vs-harris-new-polls-reveal-this-candidate-is-outperforming-in-swing-states" target="_blank" rel="noreferrer noopener">Trump Vs Harris: New Polls Reveal This Candidate Is Outperforming In Swing States</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Nate Silver's Forecast: Kamala Harris Retakes Lead Over Donald Trump

In the wake of a recent Secret Service probe into Elon Musk&#8216;s online remarks, billionaire entrepreneur Mark Cuban has come to the defense of the Tesla Inc. CEO&#8217;s contentious <a href="https://www.benzinga.com/news/24/07/39999410/what-a-second-trump-presidency-would-mean-for-elon-musk-and-his-many-ventures">social media conduct</a>.
What Happened: In a recent podcast <a href="https://youtu.be/QqDPrv8oFyY?feature=shared">interview</a>, Cuban characterized Musk&#8217;s online conduct as &#8220;kind of insane&#8221; but not out of character for the Tesla chief.
The dialogue ensued following Musk&#8217;s recent jest about pop icon Taylor Swift&#8216;s endorsement of Vice President Kamala Harris for the presidency. Cuban, who has previously corresponded with Musk, stood up for the tycoon&#8217;s comedic style. In the interview Cuban said that Musk&#8217;s joke was &#8220;kind of insane&#8221; and defended him by saying &#8220;that&#8217;s just the kind of banter you&#8217;d expect from him.&#8221;
Cuban also said that he sent Musk a text once adding that they&#8217;re &#8220;not friends&#8221; but have communicated in the past.
&#8220;We just texted back and forth a few times and he had just had a child, and I said: &#8216;Congrats on your 90th child,'&#8221; Cuban said during the interview.
&#8220;And his response was — &#8216;Mars needs people.&#8217; Right, so that&#8217;s just Elon&#8217;s sense of humor, right? I have no problem throwing Elon under the bus, but I&#8217;ll save it for when it&#8217;s truly deserved,&#8221; he said.
Also Read: <a href="https://www.benzinga.com/news/23/04/31622549/mark-cuban-asks-elon-musk-why-hes-losing-followers-despite-paying-for-twitter-blue">Mark Cuban Asks Elon Musk Why He&#8217;s Losing Followers Despite Paying For Twitter Blue</a>
Musk&#8217;s digital behavior has previously gotten him into trouble. In 2018, a tweet about making Tesla a private company resulted in a $40 million agreement with the Securities and Exchange Commission. 
More recently, a tweet speculating about a potential assassination attempt on former President Donald Trump triggered a Secret Service investigation.
The Secret Service verified to Bloomberg that they were cognizant of Musk&#8217;s tweet but refrained from further comments due to ongoing enforcement actions. Musk removed the tweet on the same day, subsequently tagging it as a joke.
Why It Matters: Musk&#8217;s social media behavior has been a topic of controversy and legal scrutiny in the past. His tweets have not only led to legal consequences but also impacted Tesla&#8217;s stock performance. 
Cuban&#8217;s defense of Musk&#8217;s online conduct highlights the ongoing debate about the role and impact of social media in the corporate world, especially when used by high-profile executives. 
This incident underscores the potential legal and reputational risks associated with such behavior.
Read Next
<a href="https://www.benzinga.com/news/24/09/40897716/elon-musk-reacts-after-mark-cuban-says-he-would-buy-x-in-a-heartbeat">Elon Musk Reacts After Mark Cuban Says He Would Buy X &#8216;In A Heartbeat&#8217;</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

TSLA

Mark Cuban Embraces Elon Musk's Humor: 'I Have No Problem Throwing Elon Under The Bus, But I'll Save It For When It's Truly Deserved'

<a href="https://www.benzinga.com/topic/elon-musk" target="_blank" rel="noreferrer noopener">Elon Musk</a> reportedly intensified his political contributions in August, making his largest-known donation to bolster House Republicans&#8217; efforts <a href="https://www.benzinga.com/news/24/09/40958452/mark-cuban-says-elon-musk-believes-hes-much-smarter-than-trump-reveals-the-intoxicating-reason-why-t" target="_blank" rel="noreferrer noopener">to maintain a vulnerable majority</a>.
The National Republican Congressional Committee announced that it received $289,100 from Musk in August, <a target="_blank" href="https://www.politico.com/news/2024/09/20/elon-musk-political-donations-00180323" rel="noreferrer noopener">reported </a>Politico, citing a report filed with the Federal Election Commission.
Musk&#8217;s political stance has evolved significantly over the years.
In August, Musk explained his <a href="https://www.benzinga.com/news/24/08/40329702/elon-musk-who-once-queued-for-6-hours-to-shake-obamas-hand-explains-why-hes-now-supporting-trump-my" target="_blank" rel="noreferrer noopener">support for Donald Trump</a>, stating that his track record has been moderate and he has not been particularly political in the past. He revealed this during a conversation with Trump, touching on various topics from immigration to electric vehicles.
Musk, one of the world&#8217;s wealthiest individual with a net worth exceeding $250 billion, has previously donated to both Democrats and Republicans, though never in such substantial sums.
In September, Musk commented on a debate between Trump and Harris, expressing&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/09/40808912/elon-musk-says-kamala-harris-exceeded-most-peoples-expectations-but-debate-hosts-were-unfair-to-trum" rel="noreferrer noopener">dissatisfaction with the debate hosts</a> and raising concerns about the lack of discussion on the national debt crisis. He also mentioned that Harris exceeded most people&#8217;s expectations during the debate.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/09/40935662/while-elon-musk-backs-trump-for-the-white-house-his-teams-at-tesla-x-and-spacex-are-supporting-kamal" rel="noreferrer noopener"> While Elon Musk Backs Trump For The White House, His Teams At Tesla, X And SpaceX Are Supporting Kamala Harris: Employees Have Reportedly Donated Over $90K To Vice President&#8217;s Campaign</a>
Musk has increased his political engagement lately, developing a connection with Trump by funding America PAC, a pro-Trump organization. This group, which recently experienced a leadership change, is set to significantly aid in voter mobilization efforts for Trump and has begun investing in competitive House races nationwide.
It remains uncertain how much Musk will ultimately invest in the election. In July, the Wall Street Journal <a href="https://www.wsj.com/politics/elections/elon-musk-has-said-he-is-committing-around-45-million-a-month-to-a-new-pro-trump-super-pac-dda53823" target="_blank" rel="noreferrer noopener">suggested</a> he intended to contribute about $45 million monthly to support Trump, though Musk later refuted this claim. Despite Musk&#8217;s significant donation, the NRCC raised only $9.7 million in August, while its Democratic counterpart collected $22.2 million.
Recently, Musk faced backlash for a&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/09/40890277/elon-musk-says-his-now-deleted-controversial-post-after-latest-trump-assassination-which-was-labeled" rel="noreferrer noopener">controversial post on X</a>, which he later deleted. The post questioned why no one was attempting to assassinate President Joe Biden&nbsp;or Harris, following an assassination attempt on Trump. The White House labeled the post as &#8220;irresponsible.&#8221;
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39872015/teslas-elon-musk-recently-pledged-a-huge-donation-to-donald-trump-and-the-ex-president-returned-the" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Elon Musk Recently Pledged A Huge Donation To Donald Trump, And The Ex-President Returned The Favor By Criticizing EVs At The RNC</a></li>
</ul>

Elon Musk Boosts House Republicans With Record $289,100 Donation

During a recent <a href="https://www.youtube.com/watch?v=9IitdaHy6Q8">episode</a> of his podcast with comedian Tom Segura, <a href="https://www.benzinga.com/topic/joe-rogan">Joe Rogan</a> weighed in on former President Donald Trump and his time in the Oval Office. Rogan, <a href="https://www.benzinga.com/personal-finance/24/09/40909092/joe-rogan-says-education-addiction-recovery-and-homelessness-should-be-funded-more-its-a-good-id">never shy about discussing politics</a>, offered his thoughts on Donald Trump's presidency and why many people remain divided over him.
Don't Miss:
<ul>
<li>The startup behind White Castle's favorite Robot Fry Cook announces a next-generation fast food robot –<a href="https://www.benzinga.com/money/miso-robotics-flippy"> Here's how to get a share for under $5 today.</a></li>
<li>General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50/share with a $1,000 minimum.</a></li>
</ul>
In the conversation, Rogan acknowledged that Trump's time in office wasn't as extreme as some feared it would be: &#8220;Everyone&#8217;s saying he&#8217;s going to be a dictator. Well, he wasn&#8217;t a dictator. He was the president. He actually was the president for four years and the economy really did well and he really did try to cut some of the bullsh&#x2A;t down that&#8217;s going on in this country.&#8221;
However, Rogan also acknowledged what makes Trump such a hard pill to swallow for many. &#8220;The thing that freaks people out,&#8221; Rogan said, &#8220;is not his policies but who he is as a person.&#8221;&nbsp;
Trending: Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a>
According to Rogan, Trump's larger-than-life personality and off-the-cuff remarks are what unsettles people the most, especially when he's in such a powerful position. &#8220;We don't necessarily want that as the guy with his finger on the button,&#8221; Rogan added.
The topic then turned to how Trump&#8217;s <a href="https://www.benzinga.com/news/24/09/40870455/trump-vows-to-never-surrender-after-surviving-second-assassination-attempt">innate capacity for crowd entertainment – </a>which frequently involves humor and improvisation – adds to this division. Rogan acknowledged that Trump frequently &#8220;kills like a comedian&#8221; and that he can be &#8220;funny.&#8221; "He can go out there, have a crowd of people and just riff. He's funny, man," Rogan told Segura.&nbsp;
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
For Rogan, though, that&#8217;s not the whole story. Trump may be able to make people laugh, but Rogan said that many people don&#8217;t want their president to be as entertaining as a stand-up comedian.
In the end, Rogan thinks that different people find Trump intriguing and unsettling because of his unpredictable nature. Although many people like <a href="https://www.benzinga.com/news/24/07/39761846/trump-left-bloodied-after-shots-fired-at-pennsylvania-rally-evacuated-by-secret-service">Trump&#8217;s boldness</a> and sense of humor, others are worried that someone with such a raw personality can have such a big say in how the nation is run.
Rogan also talked about Kamala Harris's debate performance, saying she did well and was &#8220;way better prepared even when it came to answering tough questions.&#8221; He gave credit to whoever was helping her with speeches and practice, saying they're doing an amazing job. "Whoever's writing those speeches getting her to delivery, coaching her – she&#8217;s nailing," Rogan said.
Read Next:
<ul>
<li>One trailblazing female with an expertise in renewable energy built a company that's bringing the EV revolution to disadvantaged communities —<a href="https://www.benzinga.com/money/dunamis-1"> here&#8217;s how you can invest at just $500</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>

Joe Rogan Says Trump 'Wasn't A Dictator And The Economy Really Did Well.' Still There's One Thing About Trump That 'Freaks People Out'

Florida Gov. <a href="https://www.benzinga.com/topic/ron-desantis">Ron DeSantis</a> (R) is not happy with his <a href="https://www.benzinga.com/markets/cannabis/24/09/40822693/gop-and-democratic-state-senators-back-floridas-cannabis-legalization-initiative-in-new-ad-as-ba">GOP colleagues</a>, whom he says are not doing enough to stop passage of Florida&#8217;s <a href="https://www.benzinga.com/topic/florida-cannabis">cannabis legalization ballot,</a> known as Amendment 3, which will be voted on at <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d" target="_blank" rel="noreferrer noopener">the upcoming November elections</a>.
"You say you're all about these issues, and then when it's time to do something about it you're nowhere to be found," DeSantis <a href="https://www.yahoo.com/news/desantis-fumes-over-gop-lawmakers-132007609.html">told</a> a gathering in a Tallahassee church. "That is what courageous leadership is all about."
<h2 class="wp-block-heading">What's The Problem?</h2>
For starters, the proposed amendment was <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">recently endorsed</a> by former president <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a> as well as Florida's <a href="https://www.benzinga.com/markets/cannabis/24/09/40879364/young-republicans-break-ranks-to-back-cannabis-legalization-is-the-gop-ready-for-a-shift-in-the-">Young Republicans</a>.
This cannabis stand-off between Trump and DeSantis seems to have many State Republicans keeping their weed views to themselves as they weigh their allegiances between the governor and former president amid a close national election and an even closer battle between the yeas and nays of legal cannabis. Although, the Florida Republican Party&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/05/38649648/ron-desantis-plan-to-scuttle-floridas-cannabis-legalization-initiative-with-his-vast-fundraising" target="_blank" rel="noreferrer noopener">voted unanimously</a>&nbsp;against the marijuana legalization amendment in May, the situation has drastically changed since then.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40937911/desantis-backed-anti-cannabis-pacs-blew-through-116k-at-fundraiser-while-pro-pot-group-holds-90m">DeSantis-Backed Anti-Cannabis PACs &#8216;Blew Through&#8217; $116K At Fundraiser, While Pro-Pot Group Holds $90M War Chest</a>
<h2 class="wp-block-heading">How Deep Is The Split?</h2>
Former GOP state senator and legalization supporter Jeff Brandes <a href="https://www.politico.com/news/2024/09/19/trump-desantis-florida-marijuana-legalization-ballot-measure-00179847?is_magic_link=true&amp;template_id=OTJIR2CRKUD6&amp;template_variant_id=OTVPXN5JGTYRX">told</a> Politico that at least half of Florida Republican legislators agree with Trump, but they don't want a rift with DeSantis.
"This is just evidence that the legislature is completely impotent when it comes to taking this thing on and doing this legislatively," Brandes told the outlet. "They are unwilling to do the hard work because they don't want the smell of the devil's lettuce on them."
<h2 class="wp-block-heading">Desperate Move? DeSantis Calls Fraud Among Petition Gatherers</h2>
Meanwhile, supporters of the cannabis initiative and a proposed constitutional amendment enshrining abortion rights met the stringent requirements for gathering petition signatures in accordance with Florida law. However, DeSantis says they're not strict enough and is calling for more anti-fraud measures.
"There's a lot of money that's at stake here," DeSantis said this week,&nbsp;<a href="https://www.orlandoweekly.com/cannabis/florida-gov-desantis-defends-targeting-marijuana-petition-workers-37828705">reported</a> the Orlando Weekly. "People make money off the petition process. There&#8217;s an incentive to commit fraud. The Legislature tried to address it, but I don&#8217;t think that they&#8217;ve addressed it adequately."
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40968887/new-yorks-beleaguered-cannabis-equity-officer-resigns-after-being-cleared-of-retaliation-claims">New York&#8217;s Beleaguered Cannabis Equity Officer Resigns After Being Cleared Of Retaliation Claims</a></li>
</ul>
Photo: Courtesy of&nbsp;<a href="https://www.flickr.com/photos/cornstalker/" target="_blank" rel="noreferrer noopener">Matt Johnson</a>&nbsp;and&nbsp;<a href="https://www.flickr.com/photos/gageskidmore/" target="_blank" rel="noreferrer noopener">Gage Skidmore</a>&nbsp;on flickr

Cannabis

Government

Regulations

Legal

DeSantis Urges GOP To Oppose Cannabis Legalization As Party Splits Over Trump Marijuana Endorsement

Donald Trump has pledged to &#8220;rescue vaping&#8221; if he returns to the Oval Office, contradicting his previous stance that led to a partial<a href="https://www.benzinga.com/news/24/09/40866884/trump-vs-harris-tense-standoff-in-nail-biter-polls"> ban on some e-cigarette products.</a>
What Happened: On Friday, Trump criticized President Joe Biden and Vice President Kamala Harris in a <a href="https://truthsocial.com/@realDonaldTrump/posts/113171256073757122">post</a> on Truth Social, accusing them of wanting to &#8220;ban everything.&#8221; He also pointed out his past efforts to regulate e-cigarettes.
In 2019, Trump introduced restrictions on certain e-cigarette products, which he believes helped prevent children from vaping. 
&#8220;I saved Flavored Vaping in 2019, and it greatly helped people get off smoking. I raised the age to 21, keeping it away from the &#8216;kids.&#8217; Kamala and Joe want everything banned, killing small businesses all over the Country. I'll save Vaping again!&#8221; he said in the post.
Trump&#8217;s administration faced criticism in September 2019 when it proposed plans to ban all flavored vape products. However, Trump revised his position in January 2020, opting for a partial ban instead.
Also Read: <a href="https://www.benzinga.com/news/24/09/40869086/trump-vs-harris-new-poll-reveals-post-debate-swing-towards-this-candidate-in-key-state">Trump Vs Harris: New Poll Reveals Post-Debate Swing Towards This Candidate In Key State</a>
The partial ban restricted the sale of sweet and fruity flavored vape pods and cartridges, but allowed gas stations and convenience stores to continue selling menthol cartridges and vapes. 
It also permitted vape shops to sell a wide range of e-cigarette liquids in open-tank vaping systems, which are predominantly used by adults.
As California&#8217;s attorney general in 2015, Vice President Harris backed a bill aimed at preventing minors from accessing e-cigarettes.
Why It Matters: Trump&#8217;s recent pledge to &#8220;save vaping&#8221; comes amidst an ongoing debate about the health risks and benefits of e-cigarettes. His administration&#8217;s previous actions to regulate vaping were seen as a response to concerns about the rising use of e-cigarettes among young people. 
However, the partial ban was criticized for not going far enough to protect public health. 
Now, Trump&#8217;s promise to &#8220;rescue vaping&#8221; could signal a shift in his stance on e-cigarette regulation, potentially impacting the future of the vaping industry and public health policies.
Read Next
<a href="https://www.benzinga.com/news/24/08/40667209/trump-vs-harris-new-polls-reveal-this-candidate-is-outperforming-in-swing-states" target="_blank" rel="noreferrer noopener">Trump Vs Harris: New Polls Reveal This Candidate Is Outperforming In Swing States</a>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Trump Vows To 'Save Vaping Again' Despite Past Partial Ban. Here's How He Plans To Do It

One of the <a href="https://www.benzinga.com/news/23/06/32842246/with-363-8-billion-pounds-of-plastic-in-the-ocean-plastic-pollution-will-soon-outweigh-fish">biggest issues facing our oceans</a> is plastic waste. Damage to economies, industry, and the environment is estimated to cost the world $2.5 trillion annually.&nbsp;
But there's hope on the horizon. A nonprofit called The Ocean Cleanup, which you might have heard of before, says they're on track to eliminate the infamous Great Pacific Garbage Patch (GPGP) within the next decade.
Don't Miss:
<ul>
<li>Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a></li>
<li>General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50/share with a $1,000 minimum.</a></li>
</ul>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">What it will concretely take to clean up the Great Pacific Garbage Patch: <a href="https://t.co/z1O0easYxg">pic.twitter.com/z1O0easYxg</a>
&mdash; The Ocean Cleanup (@TheOceanCleanup) <a href="https://twitter.com/TheOceanCleanup/status/1832469990735540499?ref_src=twsrc%5Etfw">September 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The GPGP is an enormous area in the Pacific Ocean filled with plastic waste – an estimated 79,000 metric tons of it, to be exact. To put that into perspective, the patch is roughly twice the size of Texas. However, it's not a solid island of trash, but a huge environmental hazard, killing marine life, damaging ecosystems and harming human health.
Founded by then-18-year-old Boyan Slat in 2013, The Ocean Cleanup has been working on innovative ways to solve the problem of ocean plastic. Their goal is to clean up plastic from the ocean and stop more from getting there in the first place.&nbsp;
Trending: Don&#8217;t miss the real AI boom &#8211;<a href="https://www.benzinga.com/money/fundrise-innovation-fund"> here&#8217;s how to use just $10 to invest in high growth private tech companies.</a>
They've created specialized floating systems that use ocean currents to collect plastic. Over the past three years, they've removed over one million pounds of trash from the GPGP – about 0.5% of the total.
However, they now think they can get rid of everything. The Ocean Cleanup recently declared that, given $7.5 billion in funding, they could clear the entire GPGP in 10 years. Furthermore, they believe that they might complete the project in five years at a reduced cost of $4 billion with increased assistance.
Trending: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
Next year, the Ocean Cleanup will pause its operations briefly to map out "hot spots" – areas in the ocean with the most "intense plastic accumulation" – and make its future efforts even more efficient.
To raise funds, The Ocean Cleanup has also developed some creative ideas. They have turned the plastic they've collected into stylish, recyclable sunglasses that they sold for $199 each. According to the group, the proceeds from just one pair of sunglasses allowed them to clean an area the size of 24 football fields. In 2022, all the sunglasses sold out and they have reached the goal of funding the cleanup of 500,000 football fields worth of plastic.
Trending: The startup behind White Castle's favorite Robot Fry Cook announces a next-generation fast food robot –<a href="https://www.benzinga.com/money/miso-robotics-flippy"> Here's how to get a share for under $5 today.</a>
The <a href="https://www.benzinga.com/news/24/04/38430116/us-faces-mounting-plastic-waste-challenge-with-limited-recycling-solutions-after-chinas-2018-import">problem of plastic pollution</a> won&#8217;t go away by itself. It concerns the potential long-term harm that this material may create if action is not taken, as human health will be in danger, marine ecosystems will continue to deteriorate and the financial cost will only rise.&nbsp;
Boyan Slat summed it perfectly: "This environmental catastrophe has been allowed to exist, unresolved, for too long and for the first time, we can tell the world what it costs, what is needed and how long it could take. The only thing standing between us and clean oceans is money."
Read Next:
<ul>
<li>Unlock a $400 billion opportunity by investing in the future of EV infrastructure on<a href="https://www.benzinga.com/money/dunamis-1"> this startup already valued at $50 million.</a></li>
<li>Teens may never need wisdom teeth removed thanks to this MedTech Company –<a href="https://www.benzinga.com/money/triagenics"> Be an early investor for just $300 for 100 shares!</a></li>
</ul>

Ocean Plastic Pollution Is A $2.5T Problem Every Year. Cleanup Group Says They're On Track To Erase The Great Pacific Garbage Patch

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
What has been the top-performing stock so far of 2024?



If you had said server installer Super Micro Computer (NASDAQ:<a href="https://investorplace.com/stock-quotes/smci-stock-quote/">SMCI</a>), that would be a great answer. Louis Navellier&rsquo;s AI bet has surged 260% this year over AI excitement. Sezzle (NASDAQ:<a href="https://investorplace.com/stock-quotes/sezl-stock-quote/">SEZL</a>) would have been an even better response. This fintech startup has risen 280% since January.



But among large companies, the biggest winner has been Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>), a firm that&rsquo;s surged 360% since the start of the year. The company is developing a new weight-loss drug, and initial studies suggest it could be even more effective than current solutions. William White <a href="https://investorplace.com/2024/03/why-is-viking-therapeutics-vktx-stock-up-24-today/">covers the news</a> for InvestorPlace.com, our free news site.



Meanwhile, many small-cap healthcare firms have done even better. Elevation Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/elev-stock-quote/">ELEV</a>) is an early stage cancer research firm that has seen shares surge 840%. In fact, 12 of the top 20 stock performers this year (including small caps) are either biotech or pharmaceutical firms.



That&rsquo;s because biotech firms can be incredible bets. These small firms often have multibillion-dollar therapies in their pipelines&hellip; and the public only learns about them when clinical trial data is finally published.



Fortunately, these types of companies leave &ldquo;clues&rdquo; about their potential success. Medical experts and corporate insiders often know how clincial trials are unfolding well before the public is aware, and it turns out that following (legal) insider trades is one of the best ways to outperform. Corbus Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) &ndash; the fourth-best performer this year &ndash; has seen almost $50 million of insider purchases since January.



That&rsquo;s why I&rsquo;m excited to share Luke&rsquo;s most recent work. Over the past several months, he and his team have come up with a quantitative method to detect these types of biotech winners before they break out. He&rsquo;s already identified a small group of six plays in a biotech subsector that he believes could be the biggest winners. (<a href="https://secure.investorplace.com/?cid=MKT793950&amp;eid=MKT798792&amp;step=start&amp;plcid=PLC205880&amp;SNAID=%%SNAID%%&amp;email=%%emailaddr%%&amp;encryptedSnaid=%%ENCRYPTEDSNAID%%&amp;emailjobid=%%jobid%%&amp;emailname=%%emailname_%%">Get the full details here</a>).



In the meantime, our writers at InvestorPlace.com and I have also been researching top <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> to buy. To get you started, here&rsquo;s what we&rsquo;ve found:



<h2>5 Healthcare Stocks to Buy for 2024: Nuvectis (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cancer-300x169.jpg" alt="A variety of pills, pill bottles, and droppers arranged on a table in multiple bright colors."><div>Source: Shutterstock</div></div>Shares of biopharmaceutical firm Nuvectis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) soared 200% after going public at $5 per share in 2022. Chris MacDonald noted at the time that <a href="https://investorplace.com/2022/02/nvct-stock-alert-7-things-to-know-as-nuvectis-pharma-soars-200/">the intriguing oncology company</a> was an exciting bet on a novel cancer-beating therapy:




The company&rsquo;s key drug candidates include NXP800, a clinical-stage HSF1 pathway inhibitor. This drug is undergoing a Phase 1 study in patients with advanced tumors. This drug, along with NXP900, a preclinical SRC/YES1 kinase inhibitor, are ones that have a more speculative growth trajectory, given their early-stage status.




Fast forward two years, and Nuvectis has seen a sudden string of good news. In February, the U.S. Food and Drug Administration (FDA) granted the NXP800 development program both Fast Track and Orphan Drug designations. The following month, Nuvectis would report positive preliminary data for its Phase 1b clinical trial.



Perhaps the best news has been a recent $50,000 share purchase made by CEO and Chairman Ron Bentsur four days after the Phase 1b results were announced. On March 18, the 10% owner added 5,000 shares to his existing 3.2 million stake.



That&rsquo;s an incredibly bullish sign. The company&rsquo;s Phase 1b trials only included four patients, and the preliminary data is scant at best; only insiders like Bentsur would have full knowledge of efficacy. And the fact that he is adding even more to his already sizable stake suggests Bentsur knows something that markets do not.



That tells us that Nuvectis could be worth a small wager. I&rsquo;ve found <a href="https://investorplace.com/2021/11/5-cheap-stocks-set-to-double-this-month/">other 10x biotech winners before</a> based on these types of insider buys, and Nuvectis looks much like these past bets.



<h2>Eli Lilly (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>In January, my MarketMasterAI stock-picking system ranked Eli Lilly (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) as <a href="https://investorplace.com/2024/01/marketmasterai-top-500-stocks-january-2024/">the top healthcare company to buy</a>. The pharmaceutical giant came in seventh place overall.



Since then, shares of the Indiana-based firm have risen 30% on growing excitement over its GLP-1 weight loss drugs Zepbound and Mounjaro. Sales of the latter already exceeded $5 billion in 2023, and demand is so red-hot that shortages are expected throughout 2024.



Last Sunday, Dmytro Spilka wrote that Eli Lilly might now become the <a href="https://investorplace.com/2024/03/the-1-trillion-question-will-lly-tsmc-or-tsla-be-wall-streets-next-nvidia/">world&rsquo;s first trillion-dollar pharmaceutical company</a>. Zepbound, which was made available in December, recorded $175.8 million in sales within a month, smashing through analysts expectations of $75 million. And if profits continue rising at their current rate, Eli Lilly could reach that milestone as soon as this year.



Muslim Farooque goes even further and plainly calls Eli Lilly a name <a href="https://investorplace.com/2024/03/wall-streets-favorite-growth-stocks-7-names-that-could-make-you-filthy-rich/">that could make you filthy rich</a>.




A look at its spectacular Q4 results shows the incredible impact of its anti-obesity drugs on its top-line results. Q4 sales were at $9.35 billion, an extraordinary 28% increase YOY. Its anti-obesity offering in Mounjaro contributed $2.2 billion during the quarter, representing about 25% of total sales. Moreover, Zepbound, its latest weight-loss injection, generated $175.8 million in its debut quarter, with more growth expected ahead.




In short, Eli Lilly and its competitor Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) are sitting on a type of therapy that comes around only once every couple of generations. Around two-fifths of adults are overweight or obese globally, and that figure is as high as 60% in developed countries. Not only does this &ldquo;miracle weight loss drug&rdquo; work well &ndash; its market is absolutely enormous.



<h2>Schrodinger (SDGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div>Alex Sirois flags Schrodinger (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdgr-stock-quote/">SDGR</a>) as a stock to buy. The software research firm is <a href="https://investorplace.com/2024/03/shhh-7-small-cap-stocks-that-can-double-by-2025/">part biotech stock and part AI stock</a>.




In order to develop a therapeutic, biotechnology firms first have to identify molecules that have the potential to treat a target disease. It&rsquo;s a painstaking process that is becoming easier through the use of computers, machine learning, and artificial intelligence.



Schrodinger has emerged as a leading name in that space. The company essentially does two things. One, it licenses its technology to firms wishing to discover molecules with treatment potential. Two, the company is also currently building a portfolio of clinical and preclinical programs.




Schrodinger has seen significant real-world success. Sirois notes that Q4 revenues grew by more than 30%, and that Schrodinger itself maintains an ability to produce a blockbuster drug of its own. Advances in AI computing power also gives the chemical simulation firm a new edge.



Of course, Schrodinger isn&rsquo;t the only company involved in AI-related drug discovery. But Schrodinger&rsquo;s early start, rising revenues and deep pockets allows it to pour resources into research and development (R&amp;D) in a way that many competitors simply cannot. Analysts expect Schrodinger to spend over $200 million on R&amp;D this year, almost 95% of its revenues.



Luke Lango wrote about this company <a href="https://investorplace.com/2021/09/one-stock-to-dominate-biotech/">as early as 2021</a>. Accelerating growth and improving technologies suggest now could be an ideal time to revisit this moonshot bet.



<h2>IBB and XBI </h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>Finally, investors seeking a big-picture investment should read Eric&rsquo;s latest report on the <a href="https://investorplace.com/smartmoney/2024/03/two-different-flavors-of-biotech/">Two Different Flavors of Biotech</a>. In it, he explains why both the blue-chip iShares Biotechnology ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/ibb-stock-quote/">IBB</a>) and the riskier SPDR S&amp;P Biotech ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/xbi-stock-quote/">XBI</a>) are bets worth taking.



In the case of the former, more conservative pick:




Many of the biggest pharmaceutical companies in the world are paying tens of billions of dollars to snap up promising, albeit profitless, biotech companies. You could call it a biotech gold rush.



Presumably, the &ldquo;crazy&rdquo; prices major pharmaceutical companies are paying to acquire early-stage biotech companies aren&rsquo;t crazy at all. The acquiring companies must believe that they can utilize AI to quickly convert the profitless potential of their biotech acquisitions into robust profitability.




Essentially, the IBB ETF focuses on <a href="https://investorplace.com/stock-types/blue-chip-stocks/">blue-chip stocks</a>. Eight of its top 10 constituents produce profits, and its largest holdings include firms like Gilead (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a>), Regeneron (NASDAQ:<a href="https://investorplace.com/stock-quotes/regn-stock-quote/">REGN</a>) and Amgen (NASDAQ:<a href="https://investorplace.com/stock-quotes/amgn-stock-quote/">AMGN</a>). On average, these firms trade at a 22.6x forward P/E ratio, barely above its 10-year average of 19.6x.



Meanwhile, the riskier SPDR S&amp;P Biotech ETF gives greater upside potential. As Eric also notes:




When animal spirits are running hot in the stock market, the speculative XBI portfolio outperforms the relatively conservative IBB portfolio by a wide margin.




That&rsquo;s because the XBI ETF covers more speculative bets. Only one of the top 10 holdings of the XBI portfolio has booked a profit during the last 12 months. And given the stock market&rsquo;s recent rally, it&rsquo;s no surprise that XBI has risen 30%, compared to IBB&rsquo;s more muted 12%.



In either case, he believes that AI-enhanced drug discovery will help revolutionize the economics of drug discovery. Rather than pour millions of dollars into unknown cures, biotech firms may be able to virtually test these therapies first, and advance only the best candidates into human trials.



<h2>The Quant Edge</h2>



The bets you&rsquo;ve just read rely heavily on fundamental research. Insider purchases&hellip; blockbuster drugs&hellip; AI developments&hellip; these are all factors that can change the course of a company.



However, fundamental factors aren&rsquo;t always present. A lull in the biotech industry during 2016 through 2020 left few good options besides the largest firms. And insiders aren&rsquo;t always buying shares of their companies for the right reasons.



As luck would have it, Luke&rsquo;s latest project helps investors overcome this. In his <a href="https://secure.investorplace.com/?cid=MKT793950&amp;eid=MKT798792&amp;step=start&amp;plcid=PLC205880&amp;SNAID=%%SNAID%%&amp;email=%%emailaddr%%&amp;encryptedSnaid=%%ENCRYPTEDSNAID%%&amp;emailjobid=%%jobid%%&amp;emailname=%%emailname_%%">2nd Trillion-Dollar AI Trade</a> summit, he explains why his system is picking out bets that are performing even better than regular breakout stocks. And the timing for this summit couldn&rsquo;t have been better, because a certain change in policy is about to send certain <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> soaring. And thanks to Luke&rsquo;s system, he&rsquo;s been able to identify six stocks that are poised to skyrocket. He put all six of these tiny companies inside a brand-new report called The 6,000% A.I. Biotech Blueprint. <a href="https://secure.investorplace.com/?cid=MKT793950&amp;eid=MKT798792&amp;step=start&amp;plcid=PLC205880&amp;SNAID=%%SNAID%%&amp;email=%%emailaddr%%&amp;encryptedSnaid=%%ENCRYPTEDSNAID%%&amp;emailjobid=%%jobid%%&amp;emailname=%%emailname_%%">Find out how to access it here</a>.



On the date of publication, Thomas Yeung did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Tom Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung&rsquo;s Profit &amp; Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/5-healthcare-stocks-to-buy-for-2024/">5 Healthcare Stocks to Buy for 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

5 Healthcare Stocks to Buy for 2024

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvectis Pharma (NVCT – Research Report) and Invivyd...

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)

Nuvectis Pharma Q1 EPS of -$0.25

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) just reported results for the first quarter of 2024.<ul><li>Nuvectis Pharma reported earnings per share of -25 cents. This was above the analyst estimate for EPS of -40 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nvct-stock-earnings-nuvectis-pharma-for-q1-of-2024/">NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target of $21.00...

Strong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug Trials

Nuvectis Pharma: An Interesting Early Pipeline Does Not Justify A Buy

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;



Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.



Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.



Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;



One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.



Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;



The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.



REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.



The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;



Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div>Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;



The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;



The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Let&rsquo;s begin discussing Genenta Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnta-stock-quote/">GNTA</a>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.



While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.



The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.



The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.



AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;



As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.



As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.



However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;



What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines.</a>
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Penny Biotech Stocks to Triple Your Investment

Nuvectis Pharma reports Q2 results

Nuvectis Pharma (NVCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis fro...

Nuvectis Pharma: Strong Buy Rating on Solid Financials and Promising Oncology Pipeline

Nuvectis gains on FDA's orphan drug designation for cancer therapy

AFMD

AMGN

ANIX

CRBP

ELEV

FGEN

GILD

GNTA

IVVD

LPCN

REGN

RLMD

SDGR

SEZL

SMCI

VKTX

Earnings

Press Releases

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)

Health Care

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Nuvectis Pharma

Nuvectis Pharma (NVCT) Forecast

Nuvectis Pharma (NASDAQ:NVCT) Stock, Quote.Headers.trade-ideas